May 17, 2025SHILAP Revista de lepidopterología11 citationsOpen Access
Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster
Structured PICO
Does the recombinant zoster vaccine reduce the risk of herpes zoster and subsequent venous thromboembolic events in patients with inflammatory arthritis on immunomodulatory treatment?
P
Population
Patients with inflammatory arthritis on immunomodulatory treatment
I
Intervention
Recombinant zoster vaccine (Shingrix)
O
Outcome
Vaccine effectiveness and risk of venous thromboembolic events following herpes zosterhard clinical
Vaccination against herpes zoster is supported in adults with inflammatory arthritis to reduce the risk of post-infection venous thromboembolic events.
Abstract
This study showed that the effectiveness of Shingrix in patients with inflammatory arthritis on immunomodulatory treatment was 50%, and the risk of venous thromboembolic events was increased in the 60-90 days after herpes zoster, supporting the recommendation that adults with inflammatory arthritis should receive vaccination against herpes zoster to reduce the risk of such events.